Agilent Technologies
About: Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. and China representing the largest country concentrations.
Employees: 17,400
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
22% more first-time investments, than exits
New positions opened: 131 | Existing positions closed: 107
9% more capital invested
Capital invested by funds: $33.6B [Q2] → $36.7B (+$3.02B) [Q3]
2% more funds holding
Funds holding: 993 [Q2] → 1,017 (+24) [Q3]
9% less repeat investments, than reductions
Existing positions increased: 336 | Existing positions reduced: 369
4.11% less ownership
Funds ownership: 89.02% [Q2] → 84.91% (-4.11%) [Q3]
8% less funds holding in top 10
Funds holding in top 10: 13 [Q2] → 12 (-1) [Q3]
24% less call options, than puts
Call options by funds: $122M | Put options by funds: $162M
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
Barclays Luke Sergott 26% 1-year accuracy 12 / 46 met price target | 14%upside $145 | Underweight Maintained | 15 Oct 2024 |
Evercore ISI Group Vijay Kumar 49% 1-year accuracy 19 / 39 met price target | 14%upside $145 | In-Line Maintained | 1 Oct 2024 |
Wells Fargo Brandon Couillard 18% 1-year accuracy 3 / 17 met price target | 24%upside $157 | Overweight Initiated | 27 Aug 2024 |
Barclays Luke Sergott 26% 1-year accuracy 12 / 46 met price target | 6%upside $135 | Underweight Maintained | 23 Aug 2024 |
UBS Elizabeth Garcia 100% 1-year accuracy 1 / 1 met price target | 18%upside $150 | Neutral Maintained | 22 Aug 2024 |
Financial journalist opinion
Based on 5 articles about A published over the past 30 days
